NovaBay Pharmaceuticals Inc banner
N

NovaBay Pharmaceuticals Inc
XBER:B9P

Watchlist Manager
NovaBay Pharmaceuticals Inc
XBER:B9P
Watchlist
Price: 0.114 EUR -11.63% Market Closed
Market Cap: €480.5k

Net Margin

-130.3%
Current
Declining
by 8.9%
vs 3-y average of -121.4%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-130.3%
=
Net Income
$-18.6m
/
Revenue
$14.2m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-130.3%
=
Net Income
€-18.6m
/
Revenue
$14.2m

Peer Comparison

Country Company Market Cap Net
Margin
US
NovaBay Pharmaceuticals Inc
XBER:B9P
480.5k EUR
Loading...
US
Eli Lilly and Co
NYSE:LLY
964.4B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
572.6B USD
Loading...
CH
Roche Holding AG
SIX:ROG
284.4B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
297.7B USD
Loading...
UK
AstraZeneca PLC
LSE:AZN
217.3B GBP
Loading...
CH
Novartis AG
SIX:NOVN
227.3B CHF
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK
Loading...
US
Pfizer Inc
NYSE:PFE
151.1B USD
Loading...
US
Bristol-Myers Squibb Co
NYSE:BMY
120.9B USD
Loading...

Market Distribution

Lower than 86% of companies in the United States of America
Percentile
14th
Based on 15 072 companies
14th percentile
-130.3%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

NovaBay Pharmaceuticals Inc
Glance View

Market Cap
480.5k EUR
Industry
Pharmaceuticals

NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. The company is headquartered in Emeryville, California and currently employs 29 full-time employees. The company went IPO on 2007-10-26. The firm develops and sells scientifically created and clinically proven eyecare and skincare products. Its product, Avenova Antimicrobial Lid & Lash Solution is used for blepharitis and dry-eye disease and is also available directly to eyecare consumers through online distribution. Its trademarks include Avenova, CelleRx, PhaseOne, NeutroPhase, DERMAdoctor, Kakadu C, AINT Misbehavin, KP Duty, and depictions of Dr. Audrey Kunin. Avenova Spray has broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. The Company, through its subsidiary DERMAdoctor, LLC, offers approximately 30 dermatologist-developed products targeting common skin concerns, ranging from aging and blemishes to dry skin, perspiration, and keratosis pilaris.

B9P Intrinsic Value
Not Available
N
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-130.3%
=
Net Income
$-18.6m
/
Revenue
$14.2m
What is NovaBay Pharmaceuticals Inc's current Net Margin?

The current Net Margin for NovaBay Pharmaceuticals Inc is -130.3%, which is below its 3-year median of -121.4%.

How has Net Margin changed over time?

Over the last 3 years, NovaBay Pharmaceuticals Inc’s Net Margin has decreased from -111.4% to -130.3%. During this period, it reached a low of -130.3% on Apr 2, 2024 and a high of -46% on Jun 30, 2022.

Back to Top